Matthew Earnest is a Cardiology physician affiliated with University of Kansas. OpenAlex indexes 42 publications with 904 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9119 W 74th St Ste 350
Merriam, KS 662042268
Telephone
913-632-9400Provider last certified this registry record 25 Jul 2023.
Clinical trials
- Clinical Trial of the WC360 SiteSeal Adjunctive Compression Device Following Interventional Endovascular Procedures
Sponsor: Wound Care 360, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
40 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20254 payments
- Boston Scientific CorporationProgram year20255 payments
- Abbott LaboratoriesProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86.1%Beta blocker25.1%Metoprolol Succinate65%Carvedilol24%Metoprolol Tartrate8%Atenolol2%Part D<11 patientsStatin23.6%Rosuvastatin Calcium52%Atorvastatin Calcium48%Part D≥108 patients+ 12 more classes in this area
Blood & clotting
11.3%Factor Xa inhibitor5.7%Eliquis92%Xarelto8%Part D<11 patientsP2Y12 inhibitor5.5%Clopidogrel74%Brilinta26%Part D≥50 patientsMetabolism & gastrointestinal
2%Potassium supplement1.2%Potassium Chloride100%Part D<11 patientsSGLT2 inhibitor0.8%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- LEFT ATRIAL APPENDAGE MORPHOLOGY AND CHALLENGES WITH PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION
Journal of the American College of Cardiology
2020 - IMPACT OF POST PROCEDURAL ANTI-COAGULATION ON POST PROCEDURAL COMPLICATIONS AND DEVICE RELATED THROMBUS IN WATCHMAN PATIENTS: A MULTI-CENTER EXPERIENCE
Journal of the American College of Cardiology
2020 - SAFETY AND EFFICACY OF WATCHMAN DEVICE IMPLANTATION IN PATIENTS WITH VALVULAR HEART DISEASE A MULTICENTER STUDY
Journal of the American College of Cardiology
2020 - Vascular complications associated with percutaneous left ventricular assist device placement: A 10‐year US perspective
Catheterization and Cardiovascular Interventions
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Simari, MD
University of Kansas
Tara Lin, MD
University of Kansas
Diane Cibrik, MD
University of Kansas
Martin Mainster, MD
University of Kansas
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”